• The European project aims to develop an advanced solution for myocardial infarction patients through regenerative medicine and 3D printing technologies

• On the 24th and 25th of October, the partners of the initiative will gather together in Lisbon for the Consortium Annual Meeting to discuss the progress done and the next steps to be made

The members that integrate the consortium of CARDIOPATCH are facing the final sprint of the project and keep working on new advances to achieve the final goal: the development of an innovative therapeutic solution for patients that have suffered a myocardial infarction through two different fields, regenerative medicine and 3D printing technologies. 

To be specific, the partners of the European initiative are working together to obtain a stem-cell smart patch able to regenerate tissues damaged after suffering this kind of cardiovascular disease.   

In order to complete this mission, the Dr. Beatriz Pelacho, scientific coordinator of the initiative co-funded by the Interreg Sudoe Programme through the European Regional Development Fund (ERDF), has been studying in animal models the biocompatibility of the designed cellularized patches to select the best choice to fulfill with the therapeutic needs of the initiative. 

Before that, the team of CHUT analyzed the cardioprotective and proangiogenic characteristics of the adipose tissue derived stem cells (ADSC) that have been modified genetically to develop the therapeutic patch and the partner FIRHSCHSP worked on how to maintain the proangiogenic potential of the modified ADSC to get the desired response. 

Additionally, the IBET partner has progressed in standardized production and the characterization of the different cardiac regenerative medicine products that are being developed in CARDIOPATCH. And the work made by IBMM these months has been essential to select the most optimal functionalized patch for the implantation on the animal model.   

Finally, the partner Leartiker has advanced on the 3D printing products of the project with the development of a new system for the implantation of the patch in the heart and a new system for the production and transport of the cellularized patch. 

Meeting in Lisbon

All these progresses will be highlighted and discussed at the Consortium Annual Meeting that will be held in Lisbon on the 24th and 25th of October of 2022. 

The partners of CARDIOPATCH will present their main advances on the different work packages of the project and the following steps to be made in the final months of this initiative that kicked off in December 2019 and has its conclusion date scheduled for April 2023.

Led by Clínica Universidad de Navarra (CUN), CARDIOPATCH includes partners from Spain, France and Portugal: CIMA Universidad de Navarra, via the Foundation for Applied Medical Research, Leartiker Technology Center, Fundació Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, communication agency GUK, Centre Hospitalier Universitaire de Toulouse, the University of Montpellier (UM) - Institut des Biomolécules Max Mousseron (IBMM), GenIbet Biopharmaceuticals and the Instituto de Biologia Experimental e Tecnológica.